Affinity Asset Advisors LLC Sells 1,455,000 Shares of Autolus Therapeutics PLC Sponsored ADR $AUTL

Key Points

• Affinity Asset Advisors LLC has reduced its stake in Autolus Therapeutics PLC by 32.3%, now holding approximately 1.14% of the company, valued at $4.7 million.
• Despite selling shares, multiple institutional investors, including Wellington Management Group and Invesco Ltd., have increased their positions in Autolus Therapeutics during the first quarter.
• Analyst ratings are generally positive for Autolus Therapeutics, with an average rating of "Buy" and a consensus price target of $9.12, although recent share price declines have seen the stock down 8.6%.

Affinity Asset Advisors LLC reduced its holdings in Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report) by 32.3% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 3,045,000 shares of the company's stock after selling 1,455,000 shares during the quarter. Affinity Asset Advisors LLC owned approximately 1.14% of Autolus Therapeutics worth $4,720,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Jane Street Group LLC acquired a new position in Autolus Therapeutics in the 4th quarter valued at approximately $26,000. Barclays PLC increased its position in Autolus Therapeutics by 1,094.3% in the 4th quarter. Barclays PLC now owns 11,859 shares of the company's stock valued at $28,000 after acquiring an additional 10,866 shares during the period. Virtus ETF Advisers LLC increased its position in Autolus Therapeutics by 29.9% in the 4th quarter. Virtus ETF Advisers LLC now owns 26,429 shares of the company's stock valued at $62,000 after acquiring an additional 6,081 shares during the period. Invesco Ltd. increased its position in Autolus Therapeutics by 53.3% in the 1st quarter. Invesco Ltd. now owns 32,738 shares of the company's stock valued at $51,000 after acquiring an additional 11,381 shares during the period. Finally, OMERS ADMINISTRATION Corp acquired a new position in Autolus Therapeutics in the 4th quarter valued at approximately $85,000. 72.83% of the stock is currently owned by institutional investors and hedge funds.

Autolus Therapeutics Trading Down 4.5%

NASDAQ AUTL traded down $0.07 on Friday, hitting $1.50. 2,140,325 shares of the company were exchanged, compared to its average volume of 2,840,203. The company has a market cap of $399.21 million, a PE ratio of -1.79 and a beta of 1.90. Autolus Therapeutics PLC Sponsored ADR has a 12 month low of $1.11 and a 12 month high of $5.00. The stock has a fifty day moving average of $2.22 and a 200-day moving average of $1.86.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.06. The business had revenue of $13.50 million for the quarter, compared to analyst estimates of $12.92 million. On average, analysts expect that Autolus Therapeutics PLC Sponsored ADR will post -0.94 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. Wells Fargo & Company reduced their price objective on shares of Autolus Therapeutics from $6.00 to $5.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 13th. Needham & Company LLC reaffirmed a "buy" rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a research note on Monday, July 21st. Finally, Wall Street Zen raised shares of Autolus Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 16th. Five analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Autolus Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $9.12.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.